Genmab — Oktober 2018

[Davor]

GB - det må være open label studiet de forventer nogle data på i år på TV? https://clinicaltrials.gov/ct2/show/NCT03485209?cond=tisotumab&rank=4

[Davor]

Men det er vel cervical studiet, der bliver mest spændende. Ved vi hvornår forventer man readout på det? https://clinicaltrials.gov/ct2/show/NCT03438396?cond=tisotumab&rank=3

[Sukkeralf]

Angående mit skriv i morges, så checkede jeg lige op med Rachel - og Janssen må gerne præsentere MAIA data på ASH, hvis de skulle få en late breaker, før registreringsansøgningen er indsendt

[Sukkeralf]

Please lad dem få det

[Davor]

Jeg må sige, at jeg er spændt på TV. Det er jo en forsvindende lille del af selskabet det udgør, men er stor tilhænger af at man begynder at få opbygget sin egen kommercielle organisation. TV kan være et rigtigt godt grundlag at gøre det på, da det kræver en lille højt specialiseret org, hvilket man jo nemt kan købe sig til ...

[E_L]

there are only 6 slots for late breakers… it will not be easy... Then again, JNJ is a BIG ASH sponsor

[nohope]

No use to "censor" MAIA, it will the word of the day anyway.

[Bulder]

Rolig Sukker, de får både Maia og Cass med Begge er gamechangers.

[E_L]

not so sure @nohope, CAR-t is much more sexy these days… But I 'hope' you are right

[GeorgeBest]

Inteteresante synspunkter Davor. Jeg er sikker på du kan få en rigtig god diskussion med JørgenVarnæs om TV strategien....;-)

[E_L]

nooooo GB!! not again

[dohk]

BCMAxCD3 is also getting sexier and perhaps the biggest treat to dara way out in the future. We will
see more result on this at ASH.

[dohk]

Interesting when we will see the first mab combo...janssen will perhaps try BMCAxCD3 + dara...price is properly the biggest problem.

[E_L]

unfortunately nobody seems to know JNJ/Genmab are also working a BCMAxCD3, everyone seems to focus on GSK...

[dohk]

treat=threat...big difference in
meaning;-)

[dohk]

I think amgen is the biggest contender with their BCMAxCD3

[dohk]

I believe that the BCMA ADCs haven't show as good results yet compare to bispecific...but this will get a lot of focus at ASH.

[nohope]

properly - probably - not quite the same either

[dohk]

haha correct

[Solsen]

AMGNs drug was iv continuously for 7-9 days or so. Very unstable antibody. The results and especially the duration are to be very very good if they are going to have a chance.